<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Interferon beta-1a</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Interferon_beta-1a">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Interferon beta-1a</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Interferon beta-1a</b> (also <b>interferon beta 1-alpha</b>) is a cytokine in the interferon family used to treat multiple sclerosis (MS).<span class="mw-ref" id="cite_ref-pmid16207073_1-0"><a href="#cite_note-pmid16207073-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is produced by mammalian cells, while <a href="Interferon_beta-1b.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_beta-1b" title="Interferon beta-1b">interferon beta-1b</a> is produced in modified <i>E. coli</i>.<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span>  Some claims have been made that Interferons produce about an 18–38% reduction in the rate of MS relapses.<span class="mw-ref" id="cite_ref-About.com_3-0"><a href="#cite_note-About.com-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Interferon beta-1a</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/1AU1_Human_Interferon-Beta01.png" tppabs="https://ptable.com/wiki/compounds/I/m/1AU1_Human_Interferon-Beta01.png" data-file-width="2400" data-file-height="1673" data-file-type="bitmap" height="174" width="250"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Avonex, Rebif, Plegridy, as well as biosimilars</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Peginterferon+beta-1a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Peginterferon+beta-1a'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Peginterferon+beta-1a" class="external text external">by Peginterferon beta-1a</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Sub-cutaneous or Intramuscular Injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L03AB07<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L03AB07  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L03AB07'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L03AB07" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>10 hrs</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">Human interferon beta</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145258-61-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145258-61-3'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145258-61-3" class="external text external">145258-61-3</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8339  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8339'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8339" class="external text external">8339</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00060  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00060'" tppabs="https://www.drugbank.ca/drugs/DB00060" class="external text external">DB00060</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=XRO4566Q4R  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=XRO4566Q4R'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=XRO4566Q4R" class="external text external">XRO4566Q4R</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201562'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201562" class="external text external">ChEMBL1201562</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>908</sub><span>H</span><sub>1408</sub><span>N</span><sub>246</sub><span>O</span><sub>252</sub><span>S</span><sub>7</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">20<span style="margin-left:.25em;">027</span>.14</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271076&page2=Interferon+beta-1a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271076&page2=Interferon+beta-1a'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271076&page2=Interferon+beta-1a" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>Interferon beta has not been shown to slow the advance of disability.<span class="mw-ref" id="cite_ref-ncbi.nlm.nih.gov_4-0"><a href="#cite_note-ncbi.nlm.nih.gov-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> Interferons are not a cure for MS (there is no known cure); the claim is that interferons may slow the progress of the disease if started early and continued for the duration of the disease.<span class="mw-ref" id="cite_ref-pmid21205679_8-0"><a href="#cite_note-pmid21205679-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>

<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Clinically_isolated_syndrome">Clinically isolated syndrome</h3></summary>
    
<p>The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom. During a CIS, there is a subacute attack suggestive of demyelination which should be included in the spectrum of MS phenotypes.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Treatment with interferons after an initial attack decreases the risk of developing clinical definite MS.<span class="mw-ref" id="cite_ref-pmid18970977_10-0"><a href="#cite_note-pmid18970977-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-pmid21205678_11-0"><a href="#cite_note-pmid21205678-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Relapsing-remitting_MS">Relapsing-remitting MS</h3></summary>
    
<p>Medications are modestly effective at decreasing the number of attacks in relapsing-remitting multiple sclerosis<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> and in reducing the accumulation of brain lesions, which is measured using <a href="Gadolinium.htm" tppabs="https://ptable.com/wiki/compounds/A/Gadolinium" title="Gadolinium">gadolinium</a>-enhanced magnetic resonance imaging (MRI).<span class="mw-ref" id="cite_ref-pmid18970977_10-1"><a href="#cite_note-pmid18970977-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> Interferons reduce relapses by approximately 30% and their safe profile make them the first-line treatments.<span class="mw-ref" id="cite_ref-pmid18970977_10-2"><a href="#cite_note-pmid18970977-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> Nevertheless, not all the patients are responsive to these therapies. It is known that 30% of MS patients are non-responsive to Beta interferon.<span class="mw-ref" id="cite_ref-pmid18690496_13-0"><a href="#cite_note-pmid18690496-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> They can be classified in genetic, pharmacological and pathogenetic non-responders.<span class="mw-ref" id="cite_ref-pmid18690496_13-1"><a href="#cite_note-pmid18690496-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> One of the factors related to non-respondance is the presence of high levels of interferon beta neutralizing  antibodies. Interferon therapy, and specially interferon beta 1b, induces the production of  neutralizing  antibodies, usually in the second 6 months of treatment, in 5 to 30% of treated patients.<span class="mw-ref" id="cite_ref-pmid18970977_10-3"><a href="#cite_note-pmid18970977-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> Moreover, a subset of RRMS patients with specially active MS, sometimes called "rapidly worsening MS" are normally non-responders to interferon beta 1a.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<p>While more studies of the long-term effects of the drugs are needed,<span class="mw-ref" id="cite_ref-pmid21205679_8-1"><a href="#cite_note-pmid21205679-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-pmid18970977_10-4"><a href="#cite_note-pmid18970977-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span>  existing data on the effects of interferons indicate that early-initiated long-term therapy is safe and it is related to better outcomes.<span class="mw-ref" id="cite_ref-pmid21205679_8-2"><a href="#cite_note-pmid21205679-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Implant.png" tppabs="https://ptable.com/wiki/compounds/I/m/Implant.png" data-file-width="2048" data-file-height="1536" data-file-type="bitmap" height="165" width="220"><div class="thumbcaption" style="text-align: left">Injectable medications can produce irritation or bruises at injection site. The bruise depicted was produced by a subcutaneous injection.</div></div></div>

<p>Interferon beta-1a is available only in injectable forms, and can cause skin reactions at the injection site that may include cutaneous necrosis. Skin reactions with interferon beta are more common with subcutaneous administration and vary greatly in their clinical presentation.<span class="mw-ref" id="cite_ref-pmid10563602_16-0"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> They usually appear within the first month of treatment albeit their frequence and importance diminish after six months of treatment.<span class="mw-ref" id="cite_ref-pmid10563602_16-1"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Skin reactions are more prevalent in women.<span class="mw-ref" id="cite_ref-pmid10563602_16-2"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Mild skin reactions usually do not impede treatment whereas necroses appear in around 5% of patients and lead to the discontinuation of the therapy.<span class="mw-ref" id="cite_ref-pmid10563602_16-3"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Also over time, a visible dent at the injection site due to the local destruction of fat tissue, known as lipoatrophy, may develop, however, this rarely occurs with interferon treatment.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>Interferons, a subclass of cytokines, are produced in the body during illnesses such as influenza in order to help fight the infection. They are responsible for many of the symptoms of influenza infections, including fever, muscle aches, fatigue, and headaches.<span class="mw-ref" id="cite_ref-pmid16253889_18-0"><a href="#cite_note-pmid16253889-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> Many patients report influenza-like symptoms hours after taking interferon beta that usually improve within 24 hours, being such symptoms related to the temporary increase of cytokines.<span class="mw-ref" id="cite_ref-pmid18970977_10-5"><a href="#cite_note-pmid18970977-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-pmid10563602_16-4"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> This reaction tends to disappear after 3 months of treatment and its symptoms can be treated with over-the-counter nonsteroidal anti-inflammatory drugs, such as <a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">ibuprofen</a>, that reduce fever and pain.<span class="mw-ref" id="cite_ref-pmid10563602_16-5"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Another common transient secondary effect with interferon-beta is a functional deterioration of already existing symptoms of the disease.<span class="mw-ref" id="cite_ref-pmid10563602_16-6"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Such deterioration is similar to the one produced in MS patients due to heat, fever or stress (Uhthoff's phenomenon), usually appears within 24 hours of treatment, is more common in the initial months of treatment, and may last several days.<span class="mw-ref" id="cite_ref-pmid10563602_16-7"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> A symptom specially sensitive to worsening is spasticity.<span class="mw-ref" id="cite_ref-pmid10563602_16-8"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Interferon-beta can also reduce numbers of white blood cells (leukopenia), lymphocytes (lymphopenia) and neutrophils (neutropenia), as well as affect liver function.<span class="mw-ref" id="cite_ref-pmid10563602_16-9"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> In most cases these effects are non-dangerous and reversible after cessation or reduction of treatment.<span class="mw-ref" id="cite_ref-pmid10563602_16-10"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Nevertheless, recommendation is that all patients should be monitored through laboratory blood analyses, including liver function tests, to ensure safe use of interferons.<span class="mw-ref" id="cite_ref-pmid10563602_16-11"><a href="#cite_note-pmid10563602-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>To help prevent injection-site reactions, patients are advised to rotate injection sites and use an aseptic injection technique. Injection devices are available to optimize the injection process.  Side effects are often onerous enough that many patients ultimately discontinue taking interferons  (or <a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">glatiramer acetate</a>, a comparable disease-modifying therapy requiring regular injections).</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Interferon beta balances the expression of pro- and anti-inflammatory agents in the brain, and reduces the number of inflammatory cells that cross the blood brain barrier.<span class="mw-ref" id="cite_ref-pmid21649449_19-0"><a href="#cite_note-pmid21649449-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Overall, therapy with interferon beta leads to a reduction of neuron inflammation.<span class="mw-ref" id="cite_ref-pmid21649449_19-1"><a href="#cite_note-pmid21649449-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Moreover, it is also thought to increase the production of nerve growth factor and consequently improve neuronal survival.<span class="mw-ref" id="cite_ref-pmid21649449_19-2"><a href="#cite_note-pmid21649449-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> In vitro, interferon beta reduces production of Th17 cells which are a subset of T lymphocytes believed to have a role in the pathophysiology of MS.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmaceutical_analogs">Pharmaceutical analogs</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Avonex">Avonex</h4></summary>
    
<p>Avonex was approved in the US in 1996, and in Europe in 1997, and is registered in more than 80 countries worldwide. It is the leading MS therapy in the US, with around 40% of the overall market, and in Europe, with around 30% of the overall market. It is produced by the Biogen biotechnology company, originally under competition protection in the US under the Orphan Drug Act.</p>

<p>Avonex is sold in three formulations, a lyophilized powder requiring reconstitution, a pre-mixed liquid syringe kit, and a pen; it is administered once per week via intramuscular injection.</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Rebif">Rebif</h4></summary>
    
<p>Rebif is a disease-modifying drug (DMD) used to treat multiple sclerosis in cases of clinically isolated syndromes as well as relapsing forms of multiple sclerosis and is similar to the interferon beta protein produced by the human body. It is co-marketed by Merck Serono and Pfizer in the US under an exception to the Orphan Drug Act.  It was approved in Europe in 1998 and in the US in 2002; it has since been approved in more than 90 countries worldwide including Canada and Australia. EMD Serono has had sole rights to Rebif in the US since January 2016.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Rebif is administered via subcutaneous injection three times per week, and can be stored at room temperature for up to 30 days.</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="CinnoVex">CinnoVex</h4></summary>
    
<p>CinnoVex is the trade name of recombinant Interferon beta-1a, which is manufactured as biosimilar/biogeneric in Iran.  It is produced in a lyophilized form and sold with <a href="Distilled_water.htm" tppabs="https://ptable.com/wiki/compounds/A/Distilled_water" title="Distilled water">distilled water</a> for injection. Cinnovex was developed at the Fraunhofer Society in collaboration with CinnaGen, and is the first therapeutic protein from a Fraunhofer laboratory to be approved as biogeneric / biosimilar medicine. There are several clinical studies to prove the similarity of CinnoVex and Avonex.<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> A more water-soluble variant is currently being investigated by the Vakzine Projekt Management (VPM) GmbH in Braunschweig, Germany.</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Plegridy">Plegridy</h4></summary>
    

<p>Plegridy is the trade name of a pegylated form of Interferon beta-1a. Plegridy's advantage is it only needs injecting once every two weeks.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Betaferon_(interferon_beta-1b)">Betaferon (interferon beta-1b)</h4></summary>
    
<p>Closely related to interferon beta-1a is <a href="Interferon_beta-1b.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_beta-1b" title="Interferon beta-1b">interferon beta-1b</a>, which is also indicated for MS, but is formulated with a different dose and administered with a different frequency. Each drug has a different safety/efficacy profile.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> Interferon beta-1b is marketed only by Bayer in the US as Betaseron, and outside the US as Betaferon.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cost_and_sales">Cost and sales</h3></summary>
    
<p>In the United States as of 2015 the cost is between US$1,284 and US$1,386 per 30 mcg vial.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> As of 2020, the National Average Drug Acquisition Cost (NADAC) in the United States for Avonex was $6,872.94 for a 30 mcg kit.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>

<p>Avonex and Rebif are under the top 10 best-selling multiple sclerosis drugs of 2013:<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>

<p>It is an example of a specialty drug that would only be available through a specialty pharmacy. This is because it requires a refrigerated chain of distribution and costs $17,000-a-year.<span class="mw-ref" id="cite_ref-ncbi_2013_29-0"><a href="#cite_note-ncbi_2013-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></p> 
<table class="wikitable">
<tbody><tr>
<th>No.</th><th>2013 Global Sales</th><th>INN</th><th>Trade names</th><th>Companies</th></tr>
<tr>
<td>1</td><td>$4.33 billion</td><td><a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></td><td>Copaxone</td><td>Teva</td></tr>
<tr>
<td><b>2</b></td><td><b>$3.00 billion</b></td><td><b>Interferon beta 1a</b></td><td><b>Avonex</b></td><td><b>Biogen Idec</b></td></tr>
<tr>
<td><b>3</b></td><td><b>$2.51 billion</b></td><td><b>Interferon beta 1a</b></td><td><b>Rebif</b></td><td><b>Merck KGaA</b></td></tr>
<tr>
<td>4</td><td>$1.93 billion</td><td>Fingolimod</td><td>Gilenya</td><td>Novartis</td></tr>
<tr>
<td>5</td><td>$1.41 billion</td><td>Natalizumab</td><td>Tysabri</td><td>Biogen Idec</td></tr>
<tr>
<td>6</td><td>$1.38 billion</td><td>Interferon beta 1b</td><td>Betaseron/Betaferon</td><td>Bayer HealthCare</td></tr>
<tr>
<td>7</td><td>$876 million</td><td><a href="Dimethyl_fumarate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethyl_fumarate" title="Dimethyl fumarate">Dimethyl fumarate</a></td><td>Tecfidera</td><td>Biogen Idec</td></tr>
<tr>
<td>8</td><td>$303 million</td><td><a href="4-Aminopyridine.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Aminopyridine" title="4-Aminopyridine">4-Aminopyridine</a></td><td>Ampyra</td><td>Acorda Therapeutics</td></tr>
<tr>
<td>9</td><td>$250 million</td><td><a href="Adrenocorticotropic_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenocorticotropic_hormone" title="Adrenocorticotropic hormone">Adrenocorticotropic hormone</a></td><td>H.P. Acthar Gel</td><td>Questcor Pharmaceuticals</td></tr>
<tr>
<td>10</td><td>$221 million</td><td>Teriflunomide</td><td>Aubagio</td><td>Sanofi</td></tr>
</tbody></table>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Clinical_trials">Clinical trials</h2></summary>
    
<p>Evidence that insufficient production of interferon beta-1a in lung cells in older people may lead to increased susceptibility to respiratory viral infections such as SARS-CoV-2 and MERS-CoV has led to investigations into whether replenishing a deficiency of this interferon can protect against the dire effects of these diseases. Company Synairgen began clinical tests of SNG001, a special inhalation formulation of interferon beta-1a in patients with COVID-19.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="COVID-19">COVID-19</h3></summary>
    


<p>The British biotech company Synairgen announced in July 2020, that clinical trials with an inhaled form of interferon beta suggest that it reduces the likeliness of a COVID-19 patient developing a severe form of the disease, such as requiring ventilation, by 79%. These claims and the underlying data have not been published in a peer-reviewed medical publication.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-pmid16207073-1"> <span id="mw-reference-text-cite_note-pmid16207073-1" class="mw-reference-text"><cite id="CITEREFMurdochLyseng-Williamson2005" class="citation journal cs1">Murdoch D, Lyseng-Williamson KA (2005). "Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis". <i>BioDrugs</i>. <b>19</b> (5): 323–5. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00063030-200519050-00005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00063030-200519050-00005'" tppabs="https://doi.org/10.2165%2F00063030-200519050-00005" class="external text external">10.2165/00063030-200519050-00005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16207073  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16207073'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16207073" class="external text external">16207073</a>.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite id="CITEREFGiovannoniMunschauerDeisenhammer2002" class="citation journal cs1">Giovannoni G, Munschauer FE, Deisenhammer F (November 2002). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1738139  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1738139'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1738139" class="external text external">"Neutralising antibodies to interferon beta during the treatment of multiple sclerosis"</a>. <i>Journal of Neurology, Neurosurgery, and Psychiatry</i>. <b>73</b> (5): 465–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fjnnp.73.5.465  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fjnnp.73.5.465'" tppabs="https://doi.org/10.1136%2Fjnnp.73.5.465" class="external text external">10.1136/jnnp.73.5.465</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1738139  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1738139'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1738139" class="external text external">1738139</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12397132  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12397132'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12397132" class="external text external">12397132</a>.</cite></span></li><li id="cite_note-About.com-3"> <span id="mw-reference-text-cite_note-About.com-3" class="mw-reference-text"><cite id="CITEREFStachowiak_PhD.2008" class="citation web cs1">Stachowiak PhD., Julie (2008). <a href="javascript:if(confirm('http://ms.about.com/od/treatments/a/AVONEX.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ms.about.com/od/treatments/a/AVONEX.htm'" tppabs="http://ms.about.com/od/treatments/a/AVONEX.htm" class="external text external">"Is Avonex Right for You?"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2008-05-07</span></span>.</cite></span></li><li id="cite_note-ncbi.nlm.nih.gov-4"> <span id="mw-reference-text-cite_note-ncbi.nlm.nih.gov-4" class="mw-reference-text"><cite id="CITEREFShiraniZhaoKarimEvans2012" class="citation journal cs1">Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H (2012). <a href="javascript:if(confirm('https://doi.org/10.1001/jama.2012.7625  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/jama.2012.7625'" tppabs="https://doi.org/10.1001/jama.2012.7625" class="external text external">"Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis"</a>. <i>JAMA</i>. <b>308</b> (3): 247–56. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.2012.7625  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.2012.7625'" tppabs="https://doi.org/10.1001%2Fjama.2012.7625" class="external text external">10.1001/jama.2012.7625</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22797642  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22797642'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22797642" class="external text external">22797642</a>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFKapposKuhleMultanenKremenchutzky2015" class="citation journal cs1">Kappos L, Kuhle J, Multanen J, Kremenchutzky M, Verdun di Cantogno E, Cornelisse P, Lehr L, Casset-Semanaz F, Issard D, Uitdehaag BM (November 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680156  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680156'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680156" class="external text external">"Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15"</a>. <i>Journal of Neurology, Neurosurgery, and Psychiatry</i>. <b>86</b> (11): 1202–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fjnnp-2014-310024  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fjnnp-2014-310024'" tppabs="https://doi.org/10.1136%2Fjnnp-2014-310024" class="external text external">10.1136/jnnp-2014-310024</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680156  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680156'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680156" class="external text external">4680156</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26374702  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26374702'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26374702" class="external text external">26374702</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite id="CITEREFCalabresiKieseierArnoldBalcer2014" class="citation journal cs1">Calabresi, Peter A; Kieseier, Bernd C; Arnold, Douglas L; Balcer, Laura J; Boyko, Alexey; Pelletier, Jean; Liu, Shifang; Zhu, Ying; Seddighzadeh, Ali; Hung, Serena; Deykin, Aaron (July 2014). "Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study". <i>The Lancet Neurology</i>. <b>13</b> (7): 657–665. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1474-4422%2814%2970068-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1474-4422%2814%2970068-7'" tppabs="https://doi.org/10.1016%2FS1474-4422%2814%2970068-7" class="external text external">10.1016/S1474-4422(14)70068-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24794721  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24794721'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24794721" class="external text external">24794721</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFJacobsCookfairRudickHerndon1996" class="citation journal cs1">Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH (March 1996). "Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)". <i>Annals of Neurology</i>. <b>39</b> (3): 285–94. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fana.410390304  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fana.410390304'" tppabs="https://doi.org/10.1002%2Fana.410390304" class="external text external">10.1002/ana.410390304</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8602746  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8602746'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8602746" class="external text external">8602746</a>.</cite></span></li><li id="cite_note-pmid21205679-8"> <span id="mw-reference-text-cite_note-pmid21205679-8" class="mw-reference-text"><cite id="CITEREFFreedman2011" class="citation journal cs1">Freedman MS (January 2011). "Long-term follow-up of clinical trials of multiple sclerosis therapies". <i>Neurology</i>. <b>76</b> (1 Suppl 1): S26-34. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2FWNL.0b013e318205051d  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2FWNL.0b013e318205051d'" tppabs="https://doi.org/10.1212%2FWNL.0b013e318205051d" class="external text external">10.1212/WNL.0b013e318205051d</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21205679  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21205679'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21205679" class="external text external">21205679</a>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFLublinReingoldCohenCutter2014" class="citation journal cs1">Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (July 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366" class="external text external">"Defining the clinical course of multiple sclerosis: the 2013 revisions"</a>. <i>Neurology</i>. <b>83</b> (3): 278–86. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2FWNL.0000000000000560  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2FWNL.0000000000000560'" tppabs="https://doi.org/10.1212%2FWNL.0000000000000560" class="external text external">10.1212/WNL.0000000000000560</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366" class="external text external">4117366</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24871874  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24871874'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24871874" class="external text external">24871874</a>.</cite></span></li><li id="cite_note-pmid18970977-10"> <span id="mw-reference-text-cite_note-pmid18970977-10" class="mw-reference-text"><cite id="CITEREFCompstonColes2008" class="citation journal cs1">Compston A, Coles A (October 2008). "Multiple sclerosis". <i>Lancet</i>. <b>372</b> (9648): 1502–17. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2808%2961620-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2808%2961620-7'" tppabs="https://doi.org/10.1016%2FS0140-6736%2808%2961620-7" class="external text external">10.1016/S0140-6736(08)61620-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18970977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18970977'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18970977" class="external text external">18970977</a>.</cite></span></li><li id="cite_note-pmid21205678-11"> <span id="mw-reference-text-cite_note-pmid21205678-11" class="mw-reference-text"><cite id="CITEREFBates2011" class="citation journal cs1">Bates D (January 2011). "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials". <i>Neurology</i>. <b>76</b> (1 Suppl 1): S14-25. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2FWNL.0b013e3182050388  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2FWNL.0b013e3182050388'" tppabs="https://doi.org/10.1212%2FWNL.0b013e3182050388" class="external text external">10.1212/WNL.0b013e3182050388</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21205678  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21205678'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21205678" class="external text external">21205678</a>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFRiceIncorvaiaMunariEbers2001" class="citation journal cs1">Rice, G. P.; Incorvaia, B.; Munari, L.; Ebers, G.; Polman, C.; D'Amico, R.; Filippini, G. (2001). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973" class="external text external">"Interferon in relapsing-remitting multiple sclerosis"</a>. <i>The Cochrane Database of Systematic Reviews</i> (4): CD002002. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD002002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD002002'" tppabs="https://doi.org/10.1002%2F14651858.CD002002" class="external text external">10.1002/14651858.CD002002</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973" class="external text external">7017973</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11687131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11687131'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11687131" class="external text external">11687131</a>.</cite></span></li><li id="cite_note-pmid18690496-13"> <span id="mw-reference-text-cite_note-pmid18690496-13" class="mw-reference-text"><cite id="CITEREFBertolottoGilli2008" class="citation journal cs1">Bertolotto A, Gilli F (September 2008). "Interferon-beta responders and non-responders. A biological approach". <i>Neurological Sciences</i>. 29 Suppl 2 (S2): S216-7. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10072-008-0941-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10072-008-0941-2'" tppabs="https://doi.org/10.1007%2Fs10072-008-0941-2" class="external text external">10.1007/s10072-008-0941-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18690496  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18690496'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18690496" class="external text external">18690496</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFButtinelliClemenziBorrielloDenaro2007" class="citation journal cs1">Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C (November 2007). "Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up". <i>European Journal of Neurology</i>. <b>14</b> (11): 1281–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1468-1331.2007.01969.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1468-1331.2007.01969.x'" tppabs="https://doi.org/10.1111%2Fj.1468-1331.2007.01969.x" class="external text external">10.1111/j.1468-1331.2007.01969.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17956449  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17956449'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17956449" class="external text external">17956449</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFBosterEdanFrohmanJaved2008" class="citation journal cs1">Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O (February 2008). "Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician". <i>The Lancet. Neurology</i>. <b>7</b> (2): 173–83. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1474-4422%2808%2970020-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1474-4422%2808%2970020-6'" tppabs="https://doi.org/10.1016%2FS1474-4422%2808%2970020-6" class="external text external">10.1016/S1474-4422(08)70020-6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18207115  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18207115'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18207115" class="external text external">18207115</a>.</cite></span></li><li id="cite_note-pmid10563602-16"> <span id="mw-reference-text-cite_note-pmid10563602-16" class="mw-reference-text"><cite id="CITEREFWaltherHohlfeld1999" class="citation journal cs1">Walther EU, Hohlfeld R (November 1999). "Multiple sclerosis: side effects of interferon beta therapy and their management". <i>Neurology</i>. <b>53</b> (8): 1622–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2Fwnl.53.8.1622  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2Fwnl.53.8.1622'" tppabs="https://doi.org/10.1212%2Fwnl.53.8.1622" class="external text external">10.1212/wnl.53.8.1622</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10563602  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10563602'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10563602" class="external text external">10563602</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFEdgarBrunetFentonMcBride2004" class="citation journal cs1">Edgar CM, Brunet DG, Fenton P, McBride EV, Green P (February 2004). <a href="javascript:if(confirm('https://doi.org/10.1017/s0317167100002845  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1017/s0317167100002845'" tppabs="https://doi.org/10.1017/s0317167100002845" class="external text external">"Lipoatrophy in patients with multiple sclerosis on glatiramer acetate"</a>. <i>The Canadian Journal of Neurological Sciences</i>. <b>31</b> (1): 58–63. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1017%2Fs0317167100002845  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1017%2Fs0317167100002845'" tppabs="https://doi.org/10.1017%2Fs0317167100002845" class="external text external">10.1017/s0317167100002845</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15038472  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15038472'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15038472" class="external text external">15038472</a>.</cite></span></li><li id="cite_note-pmid16253889-18"> <span id="mw-reference-text-cite_note-pmid16253889-18" class="mw-reference-text"><cite id="CITEREFEccles2005" class="citation journal cs1">Eccles R (November 2005). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637" class="external text external">"Understanding the symptoms of the common cold and influenza"</a>. <i>The Lancet. Infectious Diseases</i>. <b>5</b> (11): 718–25. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1473-3099%2805%2970270-X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1473-3099%2805%2970270-X'" tppabs="https://doi.org/10.1016%2FS1473-3099%2805%2970270-X" class="external text external">10.1016/S1473-3099(05)70270-X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637" class="external text external">7185637</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16253889  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16253889'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16253889" class="external text external">16253889</a>.</cite></span></li><li id="cite_note-pmid21649449-19"> <span id="mw-reference-text-cite_note-pmid21649449-19" class="mw-reference-text"><cite id="CITEREFKieseier2011" class="citation journal cs1">Kieseier BC (June 2011). "The mechanism of action of interferon-β in relapsing multiple sclerosis". <i>CNS Drugs</i>. <b>25</b> (6): 491–502. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F11591110-000000000-00000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F11591110-000000000-00000'" tppabs="https://doi.org/10.2165%2F11591110-000000000-00000" class="external text external">10.2165/11591110-000000000-00000</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21649449  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21649449'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21649449" class="external text external">21649449</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFMitsdoerfferKuchroo2009" class="citation journal cs1">Mitsdoerffer M, Kuchroo V (May 2009). "New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis?". <i>Annals of Neurology</i>. <b>65</b> (5): 487–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fana.21722  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fana.21722'" tppabs="https://doi.org/10.1002%2Fana.21722" class="external text external">10.1002/ana.21722</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19479722  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19479722'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19479722" class="external text external">19479722</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><a href="javascript:if(confirm('http://biopharma.merckgroup.com/en/products/neurodegenerative_diseases/multiple_sclerosis/rebif/rebif.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://biopharma.merckgroup.com/en/products/neurodegenerative_diseases/multiple_sclerosis/rebif/rebif.html'" tppabs="http://biopharma.merckgroup.com/en/products/neurodegenerative_diseases/multiple_sclerosis/rebif/rebif.html" class="external text external">Rebif; July 29, 2016</a></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><a href="javascript:if(confirm('http://www.prnewswire.com/news-releases/emd-serono-takes-on-exclusive-promotion-of-rebif-interferon-beta-1a-in-the-us-300205988.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.prnewswire.com/news-releases/emd-serono-takes-on-exclusive-promotion-of-rebif-interferon-beta-1a-in-the-us-300205988.html'" tppabs="http://www.prnewswire.com/news-releases/emd-serono-takes-on-exclusive-promotion-of-rebif-interferon-beta-1a-in-the-us-300205988.html" class="external text external">EMD Serono Takes on Exclusive Promotion of Rebif (interferon beta-1a) in the US; January 19, 2016</a></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFNafissiAzimiAmini-HarandiSalami2012" class="citation journal cs1">Nafissi S, Azimi A, Amini-Harandi A, Salami S, shahkarami MA, Heshmat R (September 2012). "Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial". <i>Clinical Neurology and Neurosurgery</i>. <b>114</b> (7): 986–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.clineuro.2012.02.039  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.clineuro.2012.02.039'" tppabs="https://doi.org/10.1016%2Fj.clineuro.2012.02.039" class="external text external">10.1016/j.clineuro.2012.02.039</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22429566  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22429566'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22429566" class="external text external">22429566</a>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32befa95  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32befa95'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32befa95" class="external text external">"Plegridy- peginterferon beta-1a kit Plegridy PEN- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution"</a>. <i>DailyMed</i>. 19 July 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFNikfarRahimiAbdollahi2010" class="citation journal cs1">Nikfar S, Rahimi R, Abdollahi M (October 2010). "A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type". <i>Clinical Therapeutics</i>. <b>32</b> (11): 1871–88. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.clinthera.2010.10.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.clinthera.2010.10.006'" tppabs="https://doi.org/10.1016%2Fj.clinthera.2010.10.006" class="external text external">10.1016/j.clinthera.2010.10.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21095482  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21095482'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21095482" class="external text external">21095482</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFLangreth2016" class="citation news cs1">Langreth, Robert (June 29, 2016). <a href="javascript:if(confirm('https://www.bloomberg.com/graphics/2016-drug-prices/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bloomberg.com/graphics/2016-drug-prices/'" tppabs="https://www.bloomberg.com/graphics/2016-drug-prices/" class="external text external">"Decoding Big Pharma's Secret Drug Pricing Practices"</a>. Bloomberg<span class="reference-accessdate">. Retrieved <span class="nowrap">15 July</span> 2016</span>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2020-02-12/2ghv-q5xv  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2020-02-12/2ghv-q5xv'" tppabs="https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2020-02-12/2ghv-q5xv" class="external text external">"NADAC as of 2020-02-12 | Data.Medicaid.gov"</a>. <i>Centers for Medicare and Medicaid Services</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2020-02-18</span></span>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><a href="javascript:if(confirm('http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013'" tppabs="http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013" class="external text external">Top 10 best-selling multiple sclerosis drugs of 2013; September 9, 2014</a></span></li><li id="cite_note-ncbi_2013-29"> <span id="mw-reference-text-cite_note-ncbi_2013-29" class="mw-reference-text"><cite id="CITEREFGleasonAlexanderStarnerRitter2013" class="citation journal cs1">Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND (September 2013). "Health plan utilization and costs of specialty drugs within 4 chronic conditions". <i>Journal of Managed Care Pharmacy</i>. <b>19</b> (7): 542–8. doi:<a href="javascript:if(confirm('https://doi.org/10.18553%2Fjmcp.2013.19.7.542  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.18553%2Fjmcp.2013.19.7.542'" tppabs="https://doi.org/10.18553%2Fjmcp.2013.19.7.542" class="external text external">10.18553/jmcp.2013.19.7.542</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23964615  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23964615'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23964615" class="external text external">23964615</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><a href="javascript:if(confirm('https://www.covidtrialathome.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.covidtrialathome.com/'" tppabs="https://www.covidtrialathome.com/" class="external text external">SG016 - Treatment for patients with confirmed COVID-19</a></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><a href="javascript:if(confirm('https://medicalxpress.com/news/2020-05-university-led-covid19-drug-trial-home.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medicalxpress.com/news/2020-05-university-led-covid19-drug-trial-home.html'" tppabs="https://medicalxpress.com/news/2020-05-university-led-covid19-drug-trial-home.html" class="external text external">University-led COVID19 drug trial expands into home testing</a></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite id="CITEREFRowlatt2020" class="citation news cs1">Rowlatt, Justin (2020-07-20). <a href="javascript:if(confirm('https://www.bbc.com/news/health-53467022  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bbc.com/news/health-53467022'" tppabs="https://www.bbc.com/news/health-53467022" class="external text external">"Covid treatment trial described as 'breakthrough<span class="cs1-kern-right">'</span>"</a>. <i>BBC News Online</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2020-07-20</span></span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/interferon%20beta%201a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/interferon%20beta%201a'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/interferon%20beta%201a" class="external text external">"Interferon beta-1a"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Merck_Serono" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Merck_Serono" style="font-size:114%;margin:0 4em">Merck Serono</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Products</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Avelumab</li>
<li><a href="Bisoprolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisoprolol" title="Bisoprolol">Bisoprolol</a></li>
<li><a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Cladribine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Cladribine'" tppabs="https://ptable.com/wiki/compounds/A/Cladribine" title="Cladribine">Cladribine</a></li>
<li>Efalizumab</li>
<li><a href="Gonadotropin_preparations.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin_preparations" title="Gonadotropin preparations">Gonadotropin preparations</a></li>
<li><a href="Human_chorionic_gonadotropin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin">Human chorionic gonadotropin</a></li>
<li><a href="Interferon_beta-1a.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_beta-1a" title="Interferon beta-1a">Interferon beta-1a</a></li>
<li><a href="Levothyroxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levothyroxine" title="Levothyroxine">Levothyroxine</a></li>
<li><a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">Luteinizing hormone</a></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Metformin" title="Metformin">Metformin</a></li>
<li><a href="Mitoxantrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitoxantrone" title="Mitoxantrone">Mitoxantrone</a></li>
<li>Saizen</li>
<li>Serostim</li>
<li>Tegafur/uracil</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Related</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Merck Group</li>
<li>Serono</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Immunostimulants_(L03)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunostimulants_(L03)" style="font-size:114%;margin:0 4em">Immunostimulants (L03)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Endogenous</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Cytokines</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Colony-stimulating factors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>G-CSF
<ul><li><a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a> / Lipegfilgrastim / <a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li>Lenograstim</li>
<li><i>Eflapegrastim</i></li></ul></li>
<li>GM-CSF
<ul><li>Molgramostim</li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul></li>
<li>SCF
<ul><li>Ancestim</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interferons</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>alpha</i>:
<ul><li>Albinterferon</li>
<li>Interferon alfa natural</li>
<li><span class="new">Interferon alfa 2a</span> / Peginterferon alfa-2a</li>
<li>Interferon alfa 2b / Peginterferon alfa-2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li></ul></li>
<li><i>beta</i>:
<ul><li>Interferon beta natural</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li></ul></li>
<li>Interferon gamma</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interleukins</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">Aldesleukin</a></li>
<li><a href="Oprelvekin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oprelvekin" title="Oprelvekin">Oprelvekin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other protein / peptide</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">Growth hormone</a></li>
<li>Immunocyanin</li>
<li><a href="Adenosine_deaminase.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegademase" title="Pegademase" class="mw-redirect">Pegademase</a></li>
<li>Prolactin</li>
<li>Tasonermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Female sex steroids</li>
<li><a href="Histamine_dihydrochloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine_dihydrochloride" title="Histamine dihydrochloride">Histamine dihydrochloride</a></li>
<li>Poly ICLC</li>
<li><a href="Vitamin_D.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_D" title="Vitamin D">Vitamin D</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Exogenous</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>beta-glucan
<ul><li>Lentinan</li></ul></li>
<li>heterocyclic compound
<ul><li>Plerixafor</li></ul></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">hydroxyquinoline</a>
<ul><li>Roquinimex</li></ul></li>
<li>Mifamurtide</li>
<li>oligopeptides
<ul><li><a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></li>
<li>Thymopentin</li>
<li>Thymosin α1</li>
<li>Thymulin</li></ul></li>
<li>polyribonucleotide
<ul><li>Polyinosinic:polycytidylic acid</li></ul></li>
<li><a href="Thiazolidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidine" title="Thiazolidine">thiazolidine</a>
<ul><li><a href="Pidotimod.htm" tppabs="https://ptable.com/wiki/compounds/A/Pidotimod" title="Pidotimod">Pidotimod</a></li></ul></li>
<li>vaccines
<ul><li>Bacillus Calmette–Guérin</li>
<li>Melanoma vaccine</li>
<li>Sipuleucel-T</li></ul></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Cytokine_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Cytokine_receptor_modulators" style="font-size:114%;margin:0 4em">Cytokine receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chemokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CSF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Erythropoietin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">ARA-290</span></li>
<li><span class="new">Asialo erythropoietin</span></li>
<li><span class="new">Carbamylated erythropoietin</span></li>
<li><span class="new">CNTO-530</span></li>
<li><a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a></li>
<li><a href="Epoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Epoetin_alfa" title="Epoetin alfa">Epoetin alfa</a></li>
<li>Epoetin beta</li>
<li><span class="new">Epoetin delta</span></li>
<li><span class="new">Epoetin epsilon</span></li>
<li><span class="new">Epoetin gamma</span></li>
<li><span class="new">Epoetin kappa</span></li>
<li><span class="new">Epoetin omega</span></li>
<li><span class="new">Epoetin theta</span></li>
<li>Epoetin zeta</li>
<li>Erythropoietin (EPO)</li>
<li><span class="new">Erythropoietin-Fc</span></li>
<li>Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)</li>
<li>Peginesatide</li>
<li><span class="new">Pegol sihematide (EPO-018B)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">G-CSF (CSF3)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a></li>
<li>Granulocyte colony-stimulating factor</li>
<li>Lenograstim</li>
<li><span class="new">Leridistim</span></li>
<li>Lipegfilgrastim</li>
<li><span class="new">Nartograstim</span></li>
<li><a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li><span class="new">Pegnartograstim</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GM-CSF (CSF2)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ecogramostim</span></li>
<li>Granulocyte macrophage colony-stimulating factor</li>
<li><span class="new">Milodistim</span></li>
<li>Molgramostim</li>
<li><span class="new">Regramostim</span></li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul>

<ul><li><i>Antibodies:</i> Mavrilimumab</li>
<li>Namilumab</li>
<li>Otilimab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">M-CSF (CSF1)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Cilmostim</span></li>
<li>Interleukin-34</li>
<li><span class="new">Lanimostim</span></li>
<li>Macrophage colony-stimulating factor</li>
<li><span class="new">Mirimostim</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Thrombopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Eltrombopag</li>
<li><span class="new">Pegacaristim</span></li>
<li>Promegapoietin</li>
<li>Romiplostim</li>
<li>Thrombopoietin (THPO, MGDF)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interferon</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNAR (α/β, I)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Albinterferon</li>
<li>Interferon alpha (interferon alfa, IFN-α)</li>
<li>Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)</li>
<li><span class="new">Interferon alfa 2a</span></li>
<li>Interferon alfa 2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li>
<li>Interferon beta (IFN-β) (IFNB1, <span class="new">IFNB3</span>)</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li>
<li>Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)</li>
<li>Interferon omega (IFN-ω, IFNW1)</li>
<li>Peginterferon alfa-2a</li>
<li>Peginterferon alfa-2b</li></ul>

<ul><li><i>Antibodies:</i> Anifrolumab</li>
<li>Faralimomab</li>
<li><span class="new">MEDI-545</span></li>
<li>Rontalizumab</li>
<li>Sifalimumab</li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">Bifarcept</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNGR (γ, II)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interferon gamma (IFN-γ)</li>
<li><span class="new">Interferon gamma 1b</span></li></ul>

<ul><li><i>Antibodies:</i> Emapalumab</li>
<li>Fontolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNLR (λ, III)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See IL-28R (IFNLR) here instead.</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interleukin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TNF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK<br><small>(inhibitors)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Baricitinib</li>
<li>Filgotinib</li>
<li>Momelotinib</li>
<li>Oclacitinib</li>
<li>Ruxolitinib</li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li>Upadacitinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li>Atiprimod</li>
<li><span class="new">AZD-1480</span></li>
<li>Baricitinib</li>
<li><span class="new">CHZ868</span></li>
<li>Cucurbitacin I (elatericin B, JSI-124)</li>
<li>CYT387</li>
<li>Lestaurtinib</li>
<li><span class="new">NSC-7908</span></li>
<li><span class="new">NSC-33994</span></li>
<li>Pacritinib</li>
<li>Ruxolitinib</li>
<li><span class="new">SD-1008</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li><span class="new">Cercosporamide</span></li>
<li>Decernotinib (VX-509)</li>
<li><span class="new">TCS-21311</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li><span class="new">WHI-P 154</span></li>
<li><span class="new">ZM-39923</span></li>
<li><span class="new">ZM-449829</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional cytokines:</i> Cardiotrophin 1 (CT-1)</li>
<li>FMS-like tyrosine kinase 3 ligand (FLT3L)</li>
<li>Leukemia/leukocyte inhibitory factor (LIF)</li>
<li>Oncostatin M (OSM)</li>
<li>Thymic stromal lymphopoietin (TSLP)</li></ul>

<ul><li><i>Additional cytokine receptor modulators:</i> <span class="new">Emfilermin</span></li>
<li>Lestaurtinib</li>
<li>Midostaurin</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Growth factor receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>






<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-02" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Interferon_beta-1a&oldid=970717563  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Interferon_beta-1a&oldid=970717563'" tppabs="https://en.wikipedia.org/wiki/?title=Interferon_beta-1a&oldid=970717563">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>